Skin Cancer News and Research

Latest Skin Cancer News and Research

Web conference to analyze latest trends, developments in the European melanoma skin cancer market

There are only two FDA/EMEA approved drugs currently available for treating advanced melanoma. The available drugs, however, are not completely effective and have adverse effects. Unmet needs of patients, especially those with advanced melanoma are therefore quite high and have led to a low drug adoption and market growth over the years. The future looks brighter though, with a few promising drugs in pipeline for advanced melanoma.

18 May 2010

New DVS radiation measurement device for prostate cancer treatment

John Theurer Cancer Center at Hackensack University Medical Center announced today that it is one of two cancer centers in the tri-state area currently implanting a wireless radiation sensor, known as DVS. John Theurer Cancer Center radiation oncologists can now receive data immediately post- treatment on the precise amount of radiation being delivered to tumors and surrounding tissue for prostate cancer treatments.

18 May 2010

Cancer Research UK launches new cancer centre in Leeds

LEEDS today joins a unique chain of Cancer Research UK Centres that are being launched across the UK.

18 May 2010

Large number of people do not see health-care provider for skin cancer screening: Survey

Despite the fact that skin cancer is the only cancer that can be seen on the surface of the skin, a new survey by the American Academy of Dermatology reports that a large number of people are not taking the time to examine their skin for any changes that could be warning signs of skin cancer or seeing a health-care provider for a skin cancer screening.

17 May 2010

Cell Therapeutics announces exchange agreements for 4% Convertible Senior Subordinated Notes due 2010

Cell Therapeutics, Inc. today announced that it has entered into exchange agreements with certain holders of some of the Company's outstanding 4% Convertible Senior Subordinated Notes due 2010.

17 May 2010

Each melanoma cell capable of cancer stem cell behavior: Study

Scientists at The Wistar Institute offer a new explanation for the persistent ability of melanoma cells to self-renew, one of the reasons why melanoma remains the deadliest form of skin cancer. The concept of the "dynamic stemness" of melanoma can explain why melanoma cells behave like both conventional tumor cells and cancer stem cells.

14 May 2010

Melanoma is becoming increasingly common: Mayo Clinic Women's HealthSource

Melanoma -- the most serious form of skin cancer -- is becoming increasingly common, according to the May issue of Mayo Clinic Women's HealthSource.

13 May 2010

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

“We have very good experience with Aldara in Europe and we look forward to provide AK patients with a new product with improved tolerability that builds on the efficacy of imiquimod”

12 May 2010

More genetic sites associated with increase in breast cancer risk discovered

Scientists have found five new regions of the genome that increase a woman's risk of developing breast cancer by between six and 16 per cent, according to a study in Nature Genetics today (Sunday)1.

10 May 2010

Majority of Americans concerned about skin cancer but still like tans

When it comes to tanning, dermatologists have long suspected that most people need an attitude adjustment. Now, results of a new survey by the American Academy of Dermatology (Academy) confirmed that the majority of people still idolize the bronzed look of a tan despite wanting to protect themselves from skin cancer.

10 May 2010

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

Sosei Group Corporation announce the commencement of the Phase III clinical programme by Novartis, with QVA149, a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The start of Phase III triggers a $7.5m milestone payment to Sosei.

10 May 2010

Majority of people like suntan but concerned about skin cancer

10 May 2010

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U®, Blue Light Photodynamic Therapy Illuminator.

7 May 2010

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

A prescription drug already approved to treat genital warts and skin cancer may have a new use in boosting the effectiveness of future vaccines for bacterial and viral diseases, such as hepatitis C and HIV (the AIDS virus). These findings appear in ACS' Molecular Pharmaceutics, a bi-monthly journal.

6 May 2010

New study reveals facial skin cancer occurs predominantly on left-side

In a study appearing in the Journal of the American Academy of Dermatology a Saint Louis University doctor found that facial skin cancers were predominantly on the left-side, and especially in men.

6 May 2010

Skin cancer rates going down in Alberta: Research group

It appears that people are listening to doctors' orders to protect their skin from the sun. In the largest Canadian study of non-melanoma skin cancer, Andrei Metelitsa, Gordon Jung and their research group have found skin cancer rates in Alberta are going down in men and have levelled off for women. This comes at a time when American scientists say that skin cancer rates are on the rise.

4 May 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™), today announced it signed a collaboration agreement with the John Wayne Cancer Institute (JWCI) at Saint John's Health Center in Santa Monica, California. Under the terms of the agreement, HTG and JWCI (Department of Molecular Oncology, Dave S. B. Hoon, Ph.D., Director) will collaborate to generate a novel mRNA signature that can measure the gene expression differences in melanoma and benign nevi using HTG's qNPA technology in classical surgical pathology samples.

3 May 2010

Protect eyes from sun's UV rays to decrease risk of eye diseases, disorders

With summer right around the corner, more people will be spending time outdoors and UV protection will be top of mind. Unfortunately, most people think about the protection of their skin, when they should also be considering the safety of their eyes. In fact, according to the American Optometric Association's (AOA) American Eye-Q® survey, only one-third of Americans said UV protection is the most important factor they consider when purchasing sunglasses.

3 May 2010

AVEENO Brand partners with The Skin Cancer Foundation for Road to Healthy Skin Tour program

To coincide with Skin Cancer Awareness Month, the AVEENO Brand announces its third-year partnership with The Skin Cancer Foundation for the Road to Healthy Skin Tour, a program that has been instrumental in educating people nationwide about skin cancer detection and prevention. This year, the Tour will visit over 80 locations through September.

3 May 2010

Skin Cancer News and Research

Latest Skin Cancer News and Research

Web conference to analyze latest trends, developments in the European melanoma skin cancer market

New DVS radiation measurement device for prostate cancer treatment

Cancer Research UK launches new cancer centre in Leeds

Large number of people do not see health-care provider for skin cancer screening: Survey

Cell Therapeutics announces exchange agreements for 4% Convertible Senior Subordinated Notes due 2010

Each melanoma cell capable of cancer stem cell behavior: Study

Melanoma is becoming increasingly common: Mayo Clinic Women's HealthSource

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

More genetic sites associated with increase in breast cancer risk discovered

Majority of Americans concerned about skin cancer but still like tans

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

Majority of people like suntan but concerned about skin cancer

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

New study reveals facial skin cancer occurs predominantly on left-side

Skin cancer rates going down in Alberta: Research group

FDA issues advisory on prostate cancer drugs

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

Protect eyes from sun's UV rays to decrease risk of eye diseases, disorders

AVEENO Brand partners with The Skin Cancer Foundation for Road to Healthy Skin Tour program

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Skin Cancer News and Research

Latest Skin Cancer News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in